DEP® cabazitaxel presentation at ASCO 2024 Annual Meeting (ASX Announcement)

Starpharma (ASX: SPL, OTCQX: SPHRY) today provides a copy of the DEP® cabazitaxel presentation that was delivered at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting in Chicago, US. The presentation was part of an oral abstract session showcasing the final results of the DEP® cabazitaxel Phase 1/2 clinical trial.

Starpharma announces positive final DEP® irinotecan Phase 2 clinical trial results (ASX Announcement)

Starpharma announces the full results of the Phase 2 open-label clinical trial of DEP® irinotecan. The trial met its objectives, with endpoints demonstrating positive anti-tumour efficacy of DEP® irinotecan in heavily pre-treated patients with a range of difficult-to-treat, advanced, metastatic cancers, including colorectal cancer (CRC) and platinum-resistant ovarian cancer.

Investor Webinar - Starpharma Business Update

Starpharma hosted an investor webinar on Wednesday, 22 May 2024, to provide shareholders with a business update. 

Starpharma Business Update

Starpharma (ASX: SPL, OTCQX: SPHRY), dedicated to helping patients with significant illness, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology, is pleased to provide shareholders with a business update following an extensive review of strategy and operations, led by Starpharma’s CEO, Cheryl Maley, alongside the leadership team and Board of Directors.

Investor Webinar Notification – Starpharma Business Update

Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that it will host an investor webinar on Wednesday, 22 May 2024, to provide shareholders with a business update.

Quarterly Activities Report & Appendix 4C (ASX Announcement)

Starpharma (ASX: SPL, OTCQX: SPHRY), which is dedicated to enhancing the quality of life for patients with unmet medical needs, such as cancer, by creating innovative therapies using dendrimer technology, today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2024 (Q3 FY24). Starpharma’s closing cash balance as at 31 March 2024 was $26.6 million.

Which ASX companies are resurrecting abandoned drugs? Part 3

"SPL has developed its proprietary Dendrimer Enhanced Products platform (DEP) to improve the effectiveness and safety of drugs, especially cancer treatments." Read the full article in Stockhead. 

Which ASX companies are resurrecting abandoned drugs? Part 3

DEP is based on dendrimers, which are highly branched polymers, to enhance the delivery of cancer treatments and reduce toxic side effects such as neutropenia, nausea, severe diarrhoea and hair loss from chemotherapy agents. Read the full article in The Australian Business Review. 

Investor Webinar - Starpharma and Medicxi Partnership: Petalion Therapeutics (9 April 2024)

Starpharma hosted an investor webinar on Tuesday, 9 April 2024. The session focused on the ASX Announcement lodged on 8 April 2024, 'Starpharma and Medicxi Partnership Petalion Therapeutics', about the strategic partnership with Medicxi and the formation of a new company called Petalion Therapeutics Limited (“Petalion”).

Breaking new ground via an oncology treatment tech venture

Cheryl Maley, CEO of Starpharma (SPL), provides insight into the partnreship with Medicxi, materialising in Petalion Therapeutics in the UK.